Video

MPN Hero Advocates For Patients Enrolled In Clinical Trials

Kurt Schroeder, a research nurse, pushes for a patient-first mentality, especially as they participate in a clinical trial.

When asked why he likes working with patients with myeloproliferative neoplasms (MPNs), Kurt Schroeder, RN, responded with “I like working with my people.”

Schroeder, a research nurse at The University of Texas MD Anderson Cancer Center, advocates for patients amid researchers that sometimes forget they are dealing with people. Those efforts were recognized during the 2019 MPN Heroes® ceremony where he was awarded for his patient advocacy work.

At the event, CURE® had the chance to speak with Schroeder about how he makes sure patients enrolled in clinical research are given the proper treatment and, in one instance, had their treatment altered as needed to limit side effects.

TRANSCRIPTION

Other particulars of some of the studies include common medications. Sometimes the QT interval medications someone will pull that out of the air, it seems like some of the medications shouldn't necessarily probably be on the list because we’ll take transfusion requirements.

For instance, a lot of facilities where physicians will pretreat the patients before they get a transfusion with Benadryl — and Benadryl on some of the sites is listed as a QTC medication which could affect with a patient's heartbeat, but they exclude it by the protocol by a list of prohibited medications.

So I've discussed with the physician investigator before about adjusting the medication list or maybe the Benadryl could have a particular dose that they're allowed to have, and beyond that, then that dose would be excluded. So it makes it a little bit less disruptive and has less deviations to the study if they update the list.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content